Department of Psychiatry and Psychotherapy, Division of General Psychiatry, Medical University of Vienna, Vienna, Austria.
Department of Forensic Psychiatry, Ansbach, Germany.
Int J Neuropsychopharmacol. 2022 Aug 4;25(7):556-566. doi: 10.1093/ijnp/pyac005.
Successful treatment of delirium depends on the detection of the reversible contributors. Drugs with delirogenic properties are the most prevalent reversible cause of delirium.
This observational study is based on data from Arzneimittelsicherheit in der Psychiatrie, a multicenter drug surveillance program in German-speaking countries recording severe adverse drug reactions (ADRs) in psychiatric inpatients. The present study analyzes drug-induced delirium (DID) during treatment with antidepressants and antipsychotics.
A total of 436 565 psychiatric inpatients were treated with antidepressants and/or antipsychotics during the observation period from 1993 to 2016 in the participating 110 hospitals. Overall, 254 cases (0.06% of all patients treated with antidepressants and/or antipsychotics) of DID were detected. Implicated either in combination or alone (multiple drugs were implicated in 70.1% of DID), clomipramine (0.24%), amitriptyline (0.21%), and clozapine (0.18%) showed the highest incidence rates of DID. When implicated alone (98 cases overall), clozapine (0.11%) followed by amitriptyline (0.05%) were most likely causally associated with the occurrence of DID. Drugs with strong antimuscarinic properties generally exhibited higher risk of DID.
With an incidence rate of <0.1%, the use of antidepressants and antipsychotics was rarely associated with DID within the Arzneimittelsicherheit in der Psychiatrie program. Tricyclic antidepressants and clozapine were the most commonly implicated psychotropic drugs. These data support the specific role of antimuscarinic properties in DID.
成功治疗谵妄取决于发现可逆病因。具有致谵妄作用的药物是谵妄最常见的可逆转病因。
本观察性研究基于德语国家多中心药物监测计划 Arzneimittelsicherheit in der Psychiatrie 的数据,该计划记录精神科住院患者严重药物不良反应(ADR)。本研究分析了抗抑郁药和抗精神病药治疗期间药物引起的谵妄(DID)。
在参与的 110 家医院,1993 年至 2016 年期间,共有 436565 名精神科住院患者接受了抗抑郁药和/或抗精神病药治疗。总体而言,共检测到 254 例(接受抗抑郁药和/或抗精神病药治疗的所有患者的 0.06%)DID。氯米帕明(0.24%)、阿米替林(0.21%)和氯氮平(0.18%)单独或联合使用时(70.1%的 DID 涉及多种药物),发生率最高。单独使用时(共 98 例),氯氮平(0.11%)其次是阿米替林(0.05%),最有可能与 DID 的发生有关。具有强抗毒蕈碱作用的药物一般具有更高的 DID 风险。
在 Arzneimittelsicherheit in der Psychiatrie 计划中,抗抑郁药和抗精神病药的使用与 DID 的发生率<0.1%,很少相关。三环类抗抑郁药和氯氮平是最常涉及的精神药物。这些数据支持抗毒蕈碱作用在 DID 中的特定作用。